title: Subclass distribution and the secretory component of serum IgA anti-ganglioside antibodies in Guillain-Barré syndrome after Campylobacter jejuni enteritis.
abstract: Previously, we reported that IgA anti-GM1 antibody is more closely associated with preceding Campylobacter jejuni enteritis in Guillain-Barré syndrome (GBS) than are IgG and IgM antibodies. However, the mechanism of the induction of IgA anti-ganglioside antibodies is not clear. In this study, serum IgA antibodies against GM1, GM1b, and GD1a, and GalNAc-GD1a were examined in 152 GBS patients. In GBS, antecedent C. jejuni infection is closely associated with IgA antibodies, other than GM1, against GM1b. The IgA subclass distribution is completely restricted to IgA1, no secretory IgA anti-ganglioside antibody being detected. This result does not support the hypothesis that the serum IgA antibodies present in GBS after C. jejuni enteritis originate at mucosal sites, such as the gut mucosal immune system. Seventeen (85%) of 20 patients with IgA anti-ganglioside antibodies had serological evidence of C. jejuni infection and/or a history of antecedent diarrhea. Moreover, a motor nerve conduction study showed that patients with IgA antibodies frequently had axonal neuropathy, whereas none had demyelinating neuropathy. This may support the previous report that IgA isotype anti-GM1 antibodies are more closely associated with poor outcome than are the IgG or IgM isotypes. The induction mechanism of IgA anti-ganglioside antibodies must be clarified by determining whether concentrations of cytokines, which increase the IgA class switch, are elevated in patients with GBS after C. jejuni enteritis.
authors.affiliation: Department of Neurology, Dokkyo University School of Medicine, Shimotsuga, Tochigi, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Koga
authors.forename: N
authors.initials: N
authors.lastname: Yuki
authors.forename: K
authors.initials: K
authors.lastname: Hirata
mesh_terms: D000906:Antibodies / Q000032:analysis*; D000907:Antibodies, Bacterial / Q000032:analysis; D000917:Antibody Formation / Q000502:physiology; D002169:Campylobacter Infections / Q000150:complications*; D016123:Campylobacter jejuni; D004751:Enteritis / Q000150:complications / Q000276:immunology / Q000382:microbiology*; D005732:Gangliosides / Q000276:immunology*; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis / Q000097:blood / Q000276:immunology*; D008070:Lipopolysaccharides / Q000276:immunology; D011129:Polyradiculoneuropathy / Q000209:etiology / Q000276:immunology*; D012635:Secretory Component / Q000378:metabolism*
chemical_list: D000906:Antibodies; D000907:Antibodies, Bacterial; D005732:Gangliosides; D007070:Immunoglobulin A; D008070:Lipopolysaccharides; D012635:Secretory Component